Carla M. van Herpen

794 total citations
27 papers, 608 citations indexed

About

Carla M. van Herpen is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Carla M. van Herpen has authored 27 papers receiving a total of 608 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Carla M. van Herpen's work include Renal cell carcinoma treatment (4 papers), Colorectal Cancer Treatments and Studies (4 papers) and Head and Neck Cancer Studies (4 papers). Carla M. van Herpen is often cited by papers focused on Renal cell carcinoma treatment (4 papers), Colorectal Cancer Treatments and Studies (4 papers) and Head and Neck Cancer Studies (4 papers). Carla M. van Herpen collaborates with scholars based in Netherlands, France and United States. Carla M. van Herpen's co-authors include P H de Mulder, Alwin D. R. Huitema, Gosse J. Adema, Maaike W.G. Looman, Jan H.M. Schellens, Robert S. Jansen, W. M. Smit, Marcel Soesan, Tessa M. Bosch and Slinger Jansen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Carla M. van Herpen

27 papers receiving 596 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carla M. van Herpen Netherlands 14 325 195 146 113 98 27 608
Maria Vassilakopoulou Greece 14 383 1.2× 267 1.4× 143 1.0× 117 1.0× 159 1.6× 29 790
J. L. Pico France 14 211 0.6× 231 1.2× 107 0.7× 148 1.3× 282 2.9× 23 894
Seong Hyun Jeong South Korea 17 362 1.1× 216 1.1× 204 1.4× 104 0.9× 147 1.5× 67 761
Yasuyuki Nakano Japan 9 307 0.9× 421 2.2× 168 1.2× 46 0.4× 58 0.6× 18 1.1k
M. Saunders United States 12 143 0.4× 71 0.4× 71 0.5× 129 1.1× 57 0.6× 24 506
P J van Diest Netherlands 12 362 1.1× 337 1.7× 108 0.7× 65 0.6× 70 0.7× 15 823
Dominique Cazals France 9 247 0.8× 138 0.7× 68 0.5× 98 0.9× 67 0.7× 11 525
Marie Alt France 11 543 1.7× 123 0.6× 256 1.8× 148 1.3× 119 1.2× 20 748
Titia E. Lans Netherlands 14 246 0.8× 94 0.5× 185 1.3× 85 0.8× 140 1.4× 29 491

Countries citing papers authored by Carla M. van Herpen

Since Specialization
Citations

This map shows the geographic impact of Carla M. van Herpen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carla M. van Herpen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carla M. van Herpen more than expected).

Fields of papers citing papers by Carla M. van Herpen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carla M. van Herpen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carla M. van Herpen. The network helps show where Carla M. van Herpen may publish in the future.

Co-authorship network of co-authors of Carla M. van Herpen

This figure shows the co-authorship network connecting the top 25 collaborators of Carla M. van Herpen. A scholar is included among the top collaborators of Carla M. van Herpen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carla M. van Herpen. Carla M. van Herpen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Witte, Ward De, Giovanna Gattuso, Elisabetta Schiavello, et al.. (2022). Genome-Wide Analyses of Nephrotoxicity in Platinum-Treated Cancer Patients Identify Association with Genetic Variant in RBMS3 and Acute Kidney Injury. Journal of Personalized Medicine. 12(6). 892–892. 6 indexed citations
2.
3.
Boxtel, Wim van, Gerald W. Verhaegh, Dianne van Strijp, et al.. (2019). Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients. International Journal of Cancer. 146(11). 3196–3206. 24 indexed citations
4.
Lougheed, Sinéad M., Zuhir Bodalal, Carla M. van Herpen, et al.. (2019). The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial. Cancer Immunology Immunotherapy. 68(3). 503–515. 29 indexed citations
5.
Driessen, C.M.L., Mathijs P. Hendriks, E. Fiets, et al.. (2019). Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study. European Journal of Cancer. 113. 32–40. 10 indexed citations
6.
Heine, Rob ter, Nielka P. van Erp, Henk‐Jan Guchelaar, et al.. (2018). A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. British Journal of Clinical Pharmacology. 84(7). 1575–1586. 12 indexed citations
7.
Lougheed, Sinéad M., Carla M. van Herpen, Paul Hamberg, et al.. (2018). Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma. Cancer Immunology Immunotherapy. 68(2). 319–329. 13 indexed citations
8.
Erp, Nielka P. van, Carla M. van Herpen, Djoeke de Wit, et al.. (2016). A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. Clinical Pharmacokinetics. 55(11). 1447–1456. 16 indexed citations
9.
Derikx, Lauranne, Loes H.C. Nissen, Joost P.H. Drenth, et al.. (2015). Better survival of renal cell carcinoma in patients with inflammatory bowel disease. Oncotarget. 6(35). 38336–38347. 9 indexed citations
10.
Herpen, Carla M. van, Udai Banerji, Ellen C.M. Mommers, et al.. (2015). 333 Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985. European Journal of Cancer. 51. S65–S65. 10 indexed citations
11.
Küsters‐Vandevelde, Heidi V.N., Annelieke E.C.A.B. Willemsen, Patricia J.T.A. Groenen, et al.. (2014). Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor. Acta Neuropathologica Communications. 2(1). 41–41. 45 indexed citations
12.
Boers‐Sonderen, Marye J., Sasja F. Mulder, Irıs D. Nagtegaal, et al.. (2013). Severe exacerbation of Crohn’s disease during sunitinib treatment. European Journal of Gastroenterology & Hepatology. 26(2). 234–236. 6 indexed citations
13.
Vos, Filip De, Johanna M. M. Gijtenbeek, Chantal P. Bleeker‐Rovers, & Carla M. van Herpen. (2012). Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas. Critical Reviews in Oncology/Hematology. 85(3). 373–382. 26 indexed citations
14.
Boers‐Sonderen, Marye J., Ingrid M.E. Desar, Willeke A.M. Blokx, Johanna N.H. Timmer-Bonte, & Carla M. van Herpen. (2012). A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244). Anti-Cancer Drugs. 23(7). 761–764. 8 indexed citations
15.
Aben, Katja K.H., Sandra Heskamp, M.L.G. Janssen‐Heijnen, et al.. (2011). Better survival in patients with metastasised kidney cancer after nephrectomy: A population-based study in the Netherlands. European Journal of Cancer. 47(13). 2023–2032. 28 indexed citations
16.
Knegjens, J., Michael Hauptmann, Frank A. Pameijer, et al.. (2010). Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer. Head & Neck. 33(3). 375–382. 80 indexed citations
17.
Fiedler, Walter, Ingrid M.E. Desar, Sandrine Marréaud, et al.. (2008). Phase I and DCE-MRI evaluation of NGR-TNF, a novel vascular targeting agent, in patients with solid tumors (EORTC 16041). Journal of Clinical Oncology. 26(15_suppl). 3521–3521. 6 indexed citations
18.
Banerji, Udai, D. Ross Camidge, Kathryn H. Brown, et al.. (2008). The first-in-human study of the solid oral dosage form of AZD6244 (ARRY-142886): A phase I trial in patients (pts) with advanced cancer. Journal of Clinical Oncology. 26(15_suppl). 3535–3535. 6 indexed citations
19.
Bosch, Tessa M., Alwin D. R. Huitema, Valerie D. Doodeman, et al.. (2006). Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel. Clinical Cancer Research. 12(19). 5786–5793. 107 indexed citations
20.
Herpen, Carla M. van, Richard Huijbens, Maaike W.G. Looman, et al.. (2003). Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells.. PubMed. 9(8). 2950–6. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Vassilakopoulou Breakdown of academic impact, for papers by J. L. Pico Breakdown of academic impact, for papers by Seong Hyun Jeong Breakdown of academic impact, for papers by Yasuyuki Nakano Breakdown of academic impact, for papers by M. Saunders Breakdown of academic impact, for papers by P J van Diest Breakdown of academic impact, for papers by Dominique Cazals Breakdown of academic impact, for papers by Marie Alt Breakdown of academic impact, for papers by Titia E. Lans
Rankless by CCL
2026